Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: Free radical/antioxidant approach

Molecular Pharmacology

Volumn 56, Issue 3, 1999, Pages 494-506

  Kagan, Valerian E ^a,b,c   Yalowich, Jack C ^b   Borisenko, Grigory G ^a   Tyurina, Yulia Y ^a   Tyurin, Vladimir A ^a   Thampatty, Padmakumari ^b   Fabisiak, James P ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 2,2,5,7,8 PENTAMETHYLCHROMAN; ASCORBIC ACID; AZIDE; CYANIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FREE RADICAL; GLUTATHIONE; HYDROGEN PEROXIDE; MALEIMIDE DERIVATIVE; MYELOPEROXIDASE; THIOL DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER PREVENTION; CELL STRAIN HL 60; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET THERAPY; DRUG MECHANISM; DRUG OXIDATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMOGENESIS; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DNA BINDING;

EID: 0032868183     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.3.494     Document Type: Article

References (42)

1. Aplan PD, Chervinsky DS, Stanulla M and Burhans WC (1996) Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood 87:2649-2658.
2. Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J and Siegert W (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemo-therapy for testicular cancer. J Natl Cancer Inst 87:58-60.
3. Chalvardjian A and Rudnicki E (1970) Determination of lipid phosphorus in nanomolar range. Anal Biochem 38:225-226.
4. Chen H and Eastmond DA (1995) Synergistic increase in chromosomal breakage within the euchromatin induced by an interaction of the benzene metabolites phenol and hydroquinone in mice. Carcinogenesis 18:1963-1969.
5. Chen CL, Fuscoe JC, Liu Q and Relling MV (1996) Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells. Blood 88:2210-2218.
6. Corbett A H and Osheroff N (1993) When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 6:585-597.
7. Day WD, Tyurin VA, Tyurina YY, Liu M, Facey JA, Carta G, Kisin ER, Dubey RK and Kagan VE (1999) Peroxidase-catalyzed pro-versus antioxidant effects of 4-hydroxytamoxifen: Enzyme specificity and biochemical sequelae. Chem Res Toxicol 12:28-37
8. Felix CA, Lange BJ, Hosler MR, Fertala J and Bjornsti M-A (1995) Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res 55:4287-4292.
9. Fenna R, Zeng J and Davey C (1995) Structure of the green heme in myeloperoxidase. Arch Biochem Biophys 316:653-656.
10. Geurts van Kessel WSM, Hax WMA, Demel RA and Degier J (1977) High performance liquid chromatographic separation and direct ultraviolet detection of phospholipids. Biochim Biophys Acta 486:524-530.
11. Goss GD, Vincent M, Germond C, Rowen J, Dhaliwal H and Corringham R (1993) Combination chemotherapy with teniposide (VM-26) and carboplatin in small cell lung cancer. Am J Clin Oncol 16:295-300.
12. Haim N, Nemec J, Roman J and Sinha B (1987) Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res 47:5835-5840.
13. Henichart JP Waring MJ Riou JF Denny WA and Bailly C (1997) Copper-dependent oxidative and topoisomerase II-mediated DNA cleavage by a netropsin/4′-(9 acridinylamino) methanesul-fon-m-anisidide combilexin. Mol Pharmacol 51:448-461.
14. Horibe K, Matsushita T, Numata S, Miyajima Y, Katayama I, Kitabayashi T, Yanai M, Sekiguchi, N and Egi S (1993) Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis. Cancer 72:3723-3726.
15. Kagan VE, Serbinova EA and Packer L (1990) Recycling and antioxidant activity of tocopherol homologues of differing hydrocarbon chain length in liver microsomes. Arch Biochem Biophys 282:221-225.
16. Kagan VE, Yalowich JC, Day BW, Goldman RR and Stoyanovsky DA (1994) Ascorbate is the primary reductant of the phenoxyl radical of etoposide (VP-16) in the presence of thiols both in cell homogenates and in model systems. Biochemistry 33:9651-9660.
17. Kalyanaraman B, Nemec J and Sinha BK (1989) Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives. An EPR study. Biochemistry 28:4839-4846.
18. Langmuir ME, Yang J-R, LeCompte KA and Durand RE (1996) New thiol active fluorophores for intracellular thiols and glutathione measurement, in Fluorescence Microscopy and Fluorescent Probes (Slavik J ed) pp 229-234, Plenum, New York.
19. Lozzio BB and Lozzio CB (1979) Properties and usefulness of the original K562 human myelogenous leukemia cell line. Leuk Res 3:363-370.
20. Mans DRA, Lafleur MVM, Westmijze EJ, Horn IR, Bets GJ, Schuurhuis J, Lankelma J and Retel J (1992) Reactions of glutathione with the catechol, the ortho-quinone and semi-quinone free radical of etoposide. Biochem Pharm 43:1761-1768.
21. Mason RP and Ramakrishna Rao DN (1990) Thiyl free radical metabolites of thiol drugs, glutathione, and proteins. Methods Enzymol 186:318-329.
22. Nguyen L, Chatelut E, Chevreau C, Tranchand B, Lochen I, Bachaud JM, Pujol A, Houin G, Bugat R and Canal P (1998) Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 41:125-132
23. Nonaka T, Mio M, Doi M and Tasaka K (1992) Histamine-induced differentiation of HL-60 cells. The role of cAMP and protein kinase A. Biochem Pharmacol 44:1115-1121.
24. Pinnix IB, Guzman GS, Bonkovsky HL, Zaki SR and Kinkade JM Jr (1994) The post-translational processing of myeloperoxidase is regulated by the availability of heme. Arch Biochem Biophys 312:447-458.
25. Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH and Sandlund JT (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. New Engl J Med 325:1682-1687.
26. Pui CH, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, Krance RA, Mahmoud, HH, Ribeiro RC and Sandlund JT (1995) L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 9:1680-1684.
27. Rick O, Beyer J, Kingreen D, Schwelle N, Krusch A, Schleicher J, Kirsch A, Huhn D and Siegert W (1998) High-dose chemotherapy in germ cell tumours: A large single centre experience. Eur J Cancer 34:1883-1888
28. Ritov VB, Banni S, Yalowich JC, Day BW, Claycamp HG, Corongiu FP and Kagan VE (1996) Non-random peroxidation of different classes of membrane phospholipids in live cells detected by metabolically integrated cis-parinaric acid. Biochim Biophys Acta 1283:127-140.
29. Schreiber J, Foureman GL, Hughes MF, Mason RP and Eling TE (1989) Detection of glutathione thiyl free radical catalyzed by prostaglandin H synthase present in keratinocytes. J Biol Chem 264:7936-7943.
30. Sinha B and Trush M (1983) Free radical metabolism of VP-16 and inhibition of anthracycline-induced lipid peroxidation. Biochem Pharmacol 32:3495-3498.
31. Slevin ML (1991) The clinical pharmacology of etoposide. Cancer 67:319-329.
32. Smith MA, Rubinstein L, Cazenave L, Ungerleider RS, Maurer HM, Heyn R, Khan FM and Gehan E (1993) Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natnl Cancer Inst 85:554-558.
33. Stoyanovsky DS, Goldman R, Joannalagadda SS, Day BW, Claycamp HG and Kagan VE (1996) Detection and characterization of the electron paramagnetic resonance-silent glutathionyl-5.5-dimethyl-1-pyrroline N-oride adduct derived from redox cycling of phenoxyl radicals in model system and HL-60 cells. Arch Biochim Biophys 330:3-11.
34. Sugita K, Furukawa T, Tsuchida M, Okawa Y, Nakazawa S, Akatsuka J, Ohira M and Nishimura K (1993) High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Ped Hematol Oncol 15:99-104.
35. Traweek ST, Liu J, Braziel RM, Johnson RM and Byrnes RK (1995) Detection of myeloperoxidase gene expression in minimally differentiated acute myelogenous leukemia (AML-M0) using in situ hybridization. Diagn Mol Pathol 4:212-219.
36. Tyurina YY, Tyurin VA, Yalowich JC, Quinn PJ, Claycamp HG, Schor NF, Pitt BR and Kagan VE (1995) Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: Protective versus damaging effects of phenolic antioxidants. Toxicol Appl Pharmacol 131:227-288.
37. Usui N and Sinha BK (1990) Tyrosinase-induced free radical formation from VP-16-213: Relationship to cytotoxicity. Free Radic Res Commun 10:287-293.
38. Van Maanen JMS, Retel J, de Vries J and Pinedo HM (1988) Mechanisms of action of antitumor drug etoposide: A review. J Nat Cancer Inst 80:1526-1533.
39. Whitlock JA, Greer JP and Lukens JN (1991) Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer 68:600-604.
40. Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, Jacaruso D, Kamen BA and Buchanan GR (1993) Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11:209-217.
41. Yalowich JC, Tyurina YY, Tyurin VA, Allan WP and Kagan VE (1996) Reduction of phenoxyl radicals of the antitumor agent, etoposide (VP-16) by glutathione and protein sulfhydryls in human leukemia cells: Implications for cytotoxicity. Toxicol In Vitro 10:59-68.
42. Zwelling LA, Hinds M, Chan D, Mayes J, Lan Sie K, Parker E, Silberman L, Radcliffe A, Beran M and Blick M (1989) Characterization of an amsacrine-resistant line of human leukemia cells: Evidence for a drug-resistant form of topoisomerase II. J Biol Chem 264:16411-16420.